Trial NCT04368728
Publication Polack F, N Engl J Med, 2020
Primary outcome on the report: Safety: The primary end points of this trial were solicited, specific local or systemic adverse events and use of antipyretic or pain medication within 7 days after the receipt of each dose … and unsolicited adverse events … through 1 month after the second dose and unsolicited serious adverse events through 6 months after the second dose. Efficacy: The first primary end point was the efficacy of BNT162b2 against confirmed Covid-19 with onset at least 7 days after the second dose in participants who had been without serologic or virologic evidence of SARS-CoV-2 infection up to 7 days after the second dose.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.